NSCLC, which accounts for the majority of lung cancer cases, has shown promising results with vaccines [240] and targeted drugs like epidermal growth factor receptor (EGFR) inhibitors Erlotinib and Gefitinib [241]. This evidence concerns the gene EGFR and lung cancer.